全文获取类型
收费全文 | 12671篇 |
免费 | 1178篇 |
国内免费 | 239篇 |
专业分类
耳鼻咽喉 | 319篇 |
儿科学 | 71篇 |
妇产科学 | 180篇 |
基础医学 | 367篇 |
口腔科学 | 138篇 |
临床医学 | 922篇 |
内科学 | 641篇 |
皮肤病学 | 46篇 |
神经病学 | 297篇 |
特种医学 | 1201篇 |
外科学 | 756篇 |
综合类 | 1386篇 |
预防医学 | 509篇 |
眼科学 | 82篇 |
药学 | 1227篇 |
5篇 | |
中国医学 | 355篇 |
肿瘤学 | 5586篇 |
出版年
2024年 | 30篇 |
2023年 | 151篇 |
2022年 | 315篇 |
2021年 | 440篇 |
2020年 | 369篇 |
2019年 | 371篇 |
2018年 | 442篇 |
2017年 | 423篇 |
2016年 | 485篇 |
2015年 | 396篇 |
2014年 | 839篇 |
2013年 | 733篇 |
2012年 | 891篇 |
2011年 | 919篇 |
2010年 | 767篇 |
2009年 | 843篇 |
2008年 | 763篇 |
2007年 | 705篇 |
2006年 | 678篇 |
2005年 | 514篇 |
2004年 | 370篇 |
2003年 | 326篇 |
2002年 | 295篇 |
2001年 | 237篇 |
2000年 | 216篇 |
1999年 | 199篇 |
1998年 | 169篇 |
1997年 | 145篇 |
1996年 | 146篇 |
1995年 | 115篇 |
1994年 | 76篇 |
1993年 | 42篇 |
1992年 | 43篇 |
1991年 | 53篇 |
1990年 | 37篇 |
1989年 | 32篇 |
1988年 | 23篇 |
1987年 | 26篇 |
1986年 | 29篇 |
1985年 | 77篇 |
1984年 | 68篇 |
1983年 | 43篇 |
1982年 | 61篇 |
1981年 | 43篇 |
1980年 | 51篇 |
1979年 | 49篇 |
1977年 | 11篇 |
1976年 | 10篇 |
1975年 | 7篇 |
1973年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
目的利用腮腺显像研究鼻咽癌放疗后腮腺的摄取与排泄功能.方法48例鼻咽癌患者中,对38例肿瘤和肿大淋巴结行加速调强放疗(SMART),其亚临床灶和预防照射区接受常规照射;余10例行常规放疗.放疗前后均行腮腺显像,计算腮腺的放射性摄取指数(UI)及酸性刺激后排泌指数(EI),对腮腺功能损伤情况进行分析;同时记录患者口干程度并分级.结果鼻咽癌SMART组放疗后腮腺UI和EI分别下降21.9%和37.3%,中重度口干者12例;而常规放疗组腮腺功能明显下降,UI和EI分别下降56.1%和96.1%,中重度口干者9例,两者比较差异均有显著性(P<0.05).结论腮腺显像可灵敏地监测鼻咽癌放疗后腮腺功能. 相似文献
22.
Su-Ping Sun Ye-Ning Jin Hong-Peng Yang Yi Wei Zhao Dong 《World journal of gastroenterology : WJG》2007,13(39)
AIM: To evaluate the relationship between changes in serum transforming growth factor β1 (TGFβ1) level and curative effect of radiotherapy (RT) in patients with esophageal carcinoma.METHODS: Ninety patients with histologically confirmed esophageal carcinoma were enrolled. Serum samples for TGFβ1 analysis were obtained before and at the end of RT. An enzyme-linked immunosorbent assay was used to measure serum TGFβ1 level. Multivariate analysis was performed to investigate the relationship between disease status and changes in serum TGFβ1 level.RESULTS: Serum TGFβ1 level in patients with esophageal carcinoma before RT was significantly higher than that in healthy controls (P < 0.001). At the end of RT, serum TGFβ1 level was decreased in 67.82% (59/87) of the patients. The overall survival rate at 1,3 and 5 years was 48.28% (42/87), 19.54% (17/87)and 12.64% (11/87), respectively. Main causes of death were local failure and regional lymph node metastasis.In patients whose serum TGFβ1 level decreased after RT,the survival rate at 1, 3 and 5 years was 61.02% (36/59),28.81% (17/59) and 18.64% (11/59), respectively. The survival rate at 1 year was 17.86% (5/28) in patients whose serum TGFβ1 level increased after RT, and all died within 18 mo (P < 0.01).CONCLUSION: Serum TGFβ1 level may be a useful marker for monitoring disease status after RT in patients with esophageal carcinoma. 相似文献
23.
24.
hTERT启动子调控hNIS基因介导肺癌细胞碘摄取和131I治疗的实验研究 总被引:1,自引:1,他引:0
目的 构建含人端粒酶反转录酶(hTERT)核心启动子调控的人钠/碘同向转运体(hNIS)基因重组腺病毒,并靶向转染至肺癌A549细胞中特异性表达.探讨hTERT启动子调控的hNIS基因介导放射性碘治疗肿瘤的可能性.方法 应用AdEasy系统构建重组腺病毒Ad-hTERT-hNIS,同时构建巨细胞病毒(CMV)启动子调控的hNIS重组腺病毒Ad-CMV.hNIS作为阳性对照,不含hNIS的重组腺病毒Ad-CMV作为阴性对照.应用反转录.聚合酶链反应(RT-PCR)方法验证hTERT在转染肿瘤细胞中的转录活性,摄碘实验检测表达的hNIS蛋白功能,细胞克隆形成实验评价131I对转染肿瘤细胞的毒性作用.结果 成功构建重组腺病毒Ad-hTERT-hNIS、Ad-CMV-hNIS及Ad-CMV,并经PCR验证正确.RT-PCR证实hNIS cDNA能从Ad-hTERT-hNIS转染的细胞中扩增出来.Ad-hTERT-hNIS和Ad-CMV-hNIS转染的肺癌A549细胞摄碘能力比阴性对照组Ad-CMV转染的细胞分别提高了23和31倍,且摄碘能力可以被NaClO4抑制.Ad-hTERT-hNIS和Ad-CMV-hNIS转染的肺癌A549细胞均可被131I杀死,2组细胞成活率分别为(31.2±1.45)%和(23.6±4.08)%,而阴性对照组和未转染病毒组分别为(89.0 ±2.99)%和(91.2 ±4.63)%.结论 hTERT启动子调控的hNIS重组腺病毒转染肿瘤细胞后,应用131I治疗有望成为一种新的基因靶向治疗手段. 相似文献
25.
The goals of this report are: 1) to review the number needed to treat (NNT) concept, which, although well established in many sectors of medicine, is still relatively new to the radiotherapy community; 2) to discuss several clinical radiotherapy examples illustrating the inherent advantages of the NNT approach; and 3) to discuss potential future roles of the NNT concept within radiotherapy. 相似文献
26.
27.
C. Caramella F. Ferrari M. C. Bonferoni M. E. Sangalli M. De Bernardi Di Valserra F. Feletti M. R. Galmozzi 《Biopharmaceutics & drug disposition》1993,14(2):143-160
Six preparations were considered: three multiple unit dosage forms (micropellets in capsules) (D, E and G) and one matrix tablet (B) were experimental prolonged release formulations, two non-disintegrating tablets (A and C) were commercial products. The in vitro dissolution behaviour of the differing formulations was investigated using the USP XXII paddle apparatus. The in vivo study was effected on a panel of 12 healthy volunteers. The two commercial tablets (A and C) showed mean dissolution time (MDT) of 1.34 and 1.44 h and td of 91 and 92 min, respectively; for prolonged release formulations (B, E, D, and G) MDT ranged between 2.28 and 4.23 h and td between 149 and 291 min. The mean residence time (MRT) was 8.68 and 6.47 h for tablets A and C, respectively; it ranged between 9.62 and 10.24 h for the multiple unit formulations E, D, and G and was 11.27 h for matrix B. Formulation B also showed the higher apparent elimination half-life t1/2 (7.12 h), while apparent t1/2 for all the other formulations were very similar, ranging between 5.04 and 5.28 h. High variability between the various formulations was found for Cmax and AUC values, and no relationships could be established with the type of formulation. An in vitro/in vivo correlation was found for all the formulations examined on the basis of analogous parameters (MDT and MRT); (r = 0.83, p <0.05). In a few cases the Wagner-Nelson deconvolution method was applied to individual plasma level versus time curves and the corresponding absorption curves were obtained. In these cases the in vitro/in vivo correlation was tested on the basis of the comparison of the in vivo absorption curves with the in vitro dissolution profiles. This was accomplished using the ‘Levy's plot’ (per cent released versus per cent absorbed) approach and provided further support for the correlation found. 相似文献
28.
血肌酐值法预测地高辛个体化给药方案 总被引:1,自引:0,他引:1
在地高辛常规监测中,用血肌酐值法预测个体化药动学参数和给药方案。结果表明,84例病人的地高辛药物动力学参数预测值为,CL76±21ml/(kg·h),Vd7.05±1.20L/kg,T1/266±7h。预测的个体化剂量为3.1±0.9μg/(kg·d),预测的稳态血药浓度(C_(ss))为1.24±0.38μg/L,与实测C_(ss)1.2±0.4μg/L比较,差异无显著性(P>0.05)。 相似文献
29.
采用模拟在人体中使用的实测超声剂量,对体外培养的L-929株细胞进行辐照,通过细胞回复能力试验,观察回复前后的细胞增殖与抑制。对体外培养的人胚肺纤维细胞经1次及5次辐照,观察了DNA及细胞核面积的影响。并通过电镜观察了细胞超微结构的变化。上述实验结果,均提示经辐照后细胞有增殖趋向 相似文献
30.
1994年10月以来,作者有计划地对条件允许的肺癌病人,于放疗开始前1日和放疗结束后3日分别行胸部MRI检查。通过分析我们认为MR1在肺癌病人放疗前后以下方面评价中具有较大价值:1.原发肿瘤特征;2.肺门纵隔肿大淋巴结;3.原发肿瘤和肿大淋巴结与大血管关系的鉴别;4.肿块与肺不张鉴别;5.胸壁侵犯范围;6.放谢性肺纤维化与肿瘤残留或复发鉴别。 相似文献